FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
DaVita's Q3 earnings miss expectations, with lower dialysis treatments and higher costs, leading to narrowed guidance and stock decline.
Colorado sues to block Space Command move to Alabama, citing unconstitutional retaliation over mail-in voting.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
DaVita's Q3 earnings miss expectations, with lower dialysis treatments and higher costs, leading to narrowed guidance and stock decline.
Colorado sues to block Space Command move to Alabama, citing unconstitutional retaliation over mail-in voting.